When it comes to the management and treatment of patients with COVID-19, it looks from the analysis that, in both groups (diabetic and nondiabetic), patients almost required the same medications apart from Tocilizumab (monoclonal antibody against IL-6), which was required more frequently in the diabetic group and with a significant difference (p < 0.001) that could indicate the severity of COVID-19 in diabetic patients. This evidence concerns the gene IL6 and COVID-19.